Aktie LIFESTYLE DELIVERY SYSTEMS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Lifestyle Delivery Systems Inc Canadian Securities Exchange

Aktien

CA53224Y1043

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Core One Labs : Announces Non-Brokered Private Placement
Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Core One Labs Inc. announced that it has received CAD 0.2 million in funding
Core One Labs : Announces Non-Brokered Private Placement
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease
Core One Labs : Applauds Groundbreaking Research on Psilocybin as a Potential Anorexia Treatment
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease
Core One Labs : Applauds California Assembly Health Committee’s Approval of Bill to Legalize Psychedelics
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process
Core One's Vocan Files International Patent For Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs
Core One Labs : Applauds FDA’s Draft Guidance on Clinical Trials for Psychedelic Drugs
Core One Labs Says in Talks with Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday
Core One Labs Inc. in Talks with Multiple Companies to Supply Psilocybin
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CSSU Aktie
  4. Aktie
  5. Nachrichten Lifestyle Delivery Systems Inc
  6. Andere Sprachen